A Phase I and Pharmacokinetic Study of Oral Dabrafenib in Children and Adolescent Patients with Recurrent or Refractory

The 2-part, phase I/IIa, open-label study (NCT01677741) sought to determine the safety, tolerability, pharmacokinetics, and preliminary activity of dabrafenib in pediatric patients with advancedThis phase I dose-finding part treated patients ages 1 to18 years withBetween May 2013 and November 2014, 27 patients [12 male; median age, 9 years (range, 1-17 years)] withIn this first clinical trial in pediatric patients with pretreated